Jiekun Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiekun Yang has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
- Manolis Kellis
The Broad Institute of MIT and Harvard, Cambridge, USA
9 shared publications Li-Lun Ho
Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
7 shared publicationsKyriakitsa Galani
Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA
4 shared publications- Genevieve Marie Boland
Massachusetts General Hospital (MGH) Department of Surgery, MGH Krantz Center for Cancer Research, Boston, USA
3 shared publications - Laurie J. Goodyear
Section on Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
3 shared publications - Ming D. Li
Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, 450 Ray C Hunt Drive, Suite G-170, Charlottesville, VA, 22903, USA.
3 shared publications
Latest Publications
- 20 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (47)
Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma
While immune-checkpoint blockade (ICB) has revolutionized treatment of metastatic melanoma, the identification of robust biomarkers to predict the relative efficacy of single versus combination ICB has been challenging. We performed a meta-analysis of eight cohorts of patients treated with anti–PD-1 ( n = 290), anti–CTLA-4 ( n = 175), and combination anti–PD-1/anti–CTLA-4 ( n = 51) with pretreatment tumor sequencing and clinical annotations. Surprisingly, the increased response rate to combination anti–PD-1/anti–CTLA-4 compared to anti–PD-1 monotherapy was observed only in highly immune infiltrated tumors, and not in immune-low tumors. Stratifying tumors by high or low frequency of immune cells also distinguished context-dependent programs of primary resistance to single and combination ICB. Notably, hypoxia-related pathways were enriched in nonresponders to anti–PD-1 ICB in immune-high, but not immune-low, tumors. Using an independent cohort of patients with scRNA-seq data, we observed that correlates of hypoxia were associated with increased stromal tumor receptor-ligand interactions. As proof of concept, selective inhibition of HIF-2α, a component of the hypoxia pathway and highly expressed in endothelial cells and fibroblasts, in combination with anti–PD-1, controlled tumor growth in mouse models of highly immune-infiltrated tumors but not poorly immune-infiltrated tumors. Our work demonstrates how stratification by tumor immune characteristics and clinical features can lead to the rational discovery of novel therapeutic targets.
- 20 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (47)
Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma
While immune-checkpoint blockade (ICB) has revolutionized treatment of metastatic melanoma, the identification of robust biomarkers to predict the relative efficacy of single versus combination ICB has been challenging. We performed a meta-analysis of eight cohorts of patients treated with anti–PD-1 ( n = 290), anti–CTLA-4 ( n = 175), and combination anti–PD-1/anti–CTLA-4 ( n = 51) with pretreatment tumor sequencing and clinical annotations. Surprisingly, the increased response rate to combination anti–PD-1/anti–CTLA-4 compared to anti–PD-1 monotherapy was observed only in highly immune infiltrated tumors, and not in immune-low tumors. Stratifying tumors by high or low frequency of immune cells also distinguished context-dependent programs of primary resistance to single and combination ICB. Notably, hypoxia-related pathways were enriched in nonresponders to anti–PD-1 ICB in immune-high, but not immune-low, tumors. Using an independent cohort of patients with scRNA-seq data, we observed that correlates of hypoxia were associated with increased stromal tumor receptor-ligand interactions. As proof of concept, selective inhibition of HIF-2α, a component of the hypoxia pathway and highly expressed in endothelial cells and fibroblasts, in combination with anti–PD-1, controlled tumor growth in mouse models of highly immune-infiltrated tumors but not poorly immune-infiltrated tumors. Our work demonstrates how stratification by tumor immune characteristics and clinical features can lead to the rational discovery of novel therapeutic targets.
- Open Access
Epigenetically constrained astrocyte states underlie prefrontal cortex vulnerability in Down syndrome–associated Alzheimer’s disease
Down syndrome (DS), caused by trisomy 21, confers a near-universal risk for Alzheimer’s disease (AD), yet individuals exhibit marked variability in cognitive decline, suggesting the presence of cellular mechanisms that modulate vulnerability and resilience. However, these mechanisms remain poorly defined in the human brain. Here, we integrate matched single-nucleus RNA-seq and ATAC-seq profiles from the prefrontal cortex (PFC) and amygdala (AMY) of age-matched individuals with DS with and without AD (DSAD), enabling direct comparison within a shared genetic background. We identify basal astrocytes in the PFC as a selectively vulnerable cell state in DSAD, characterized by both reduced abundance and coordinated transcriptional and regulatory reprogramming. This state exhibits a shift away from homeostatic support functions, with decreased cytokine signaling and lipid-handling programs, alongside increased steroid- and nuclear receptor–associated activity. Concomitantly, chromatin accessibility profiling reveals reduced engagement of immune- and stress-responsive transcription factor programs, including AP-1, STAT, and BACH families, with linked regulatory perturbations at loci such as ABCA1, DAB2IP, and IL1RAP. Together, these findings define a previously unrecognized astrocyte state marked by epigenetic constraint and diminished responsiveness to stress and inflammatory signals, distinguishing it from classical reactive astrocyte phenotypes. Our results nominate PFC basal astrocytes as a key locus of vulnerability in DSAD and suggest that failure to mount appropriate astrocyte responses, rather than overt activation alone, may contribute to neurodegenerative progression.
Open AccessEpigenetically constrained astrocyte states underlie prefrontal cortex vulnerability in Down syndrome–associated Alzheimer’s disease
Down syndrome (DS), caused by trisomy 21, confers a near-universal risk for Alzheimer’s disease (AD), yet individuals exhibit marked variability in cognitive decline, suggesting the presence of cellular mechanisms that modulate vulnerability and resilience. However, these mechanisms remain poorly defined in the human brain. Here, we integrate matched single-nucleus RNA-seq and ATAC-seq profiles from the prefrontal cortex (PFC) and amygdala (AMY) of age-matched individuals with DS with and without AD (DSAD), enabling direct comparison within a shared genetic background. We identify basal astrocytes in the PFC as a selectively vulnerable cell state in DSAD, characterized by both reduced abundance and coordinated transcriptional and regulatory reprogramming. This state exhibits a shift away from homeostatic support functions, with decreased cytokine signaling and lipid-handling programs, alongside increased steroid- and nuclear receptor–associated activity. Concomitantly, chromatin accessibility profiling reveals reduced engagement of immune- and stress-responsive transcription factor programs, including AP-1, STAT, and BACH families, with linked regulatory perturbations at loci such as ABCA1, DAB2IP, and IL1RAP. Together, these findings define a previously unrecognized astrocyte state marked by epigenetic constraint and diminished responsiveness to stress and inflammatory signals, distinguishing it from classical reactive astrocyte phenotypes. Our results nominate PFC basal astrocytes as a key locus of vulnerability in DSAD and suggest that failure to mount appropriate astrocyte responses, rather than overt activation alone, may contribute to neurodegenerative progression.
- Open Access
STCS: A Platform-Agnostic Framework for Cell-Level Reconstruction in Sequencing-Based Spatial Transcriptomics
Sequencing-based spatial transcriptomics technologies, including Visium HD and Stereo-seq, now enable transcriptome-wide profiling at subcellular resolution. However, these platforms generate measurements over spatially barcoded units rather than biologically segmented cells, creating a fundamental bottleneck for cell-centric analysis and interpretation. Robust recon-struction of coherent single-cell transcriptomes from high-density spatial bins remains an unresolved computational challenge. Here we present STCS (Spatial Transcriptomics Cell Segmentation) , a platform-agnostic framework that reconstructs cell-level gene expression profiles by integrating nuclei segmentation with a joint transcriptomic–spatial distance model. STCS is governed by two interpretable parameters and incorporates a reference-free parameter selection strategy based on internal stability and spatial coherence metrics, enabling adaptable deployment across tissue types and technologies without requiring matched ground-truth annotations. We benchmark STCS on a Visium HD human lung cancer dataset with matched Xenium-derived cell segmentation, enabling direct cell-level validation, and on high-resolution Stereo-seq mouse brain data to assess cross-platform generalizability. Across multiple evaluation dimensions—including cell-type agreement, spatial organization, gene-expression fidelity, and compositional accuracy—STCS achieves consistent improvements over existing methods while preserving biologically coherent spatial structure. As sequencing-based spatial transcriptomics is rapidly adopted across biomedical research, STCS provides a broadly applicable and open-source solution for reconstructing cell-resolved transcriptomes, facilitating more reliable downstream analyses and cross-platform integration.
Open AccessSTCS: A Platform-Agnostic Framework for Cell-Level Reconstruction in Sequencing-Based Spatial Transcriptomics
Sequencing-based spatial transcriptomics technologies, including Visium HD and Stereo-seq, now enable transcriptome-wide profiling at subcellular resolution. However, these platforms generate measurements over spatially barcoded units rather than biologically segmented cells, creating a fundamental bottleneck for cell-centric analysis and interpretation. Robust recon-struction of coherent single-cell transcriptomes from high-density spatial bins remains an unresolved computational challenge. Here we present STCS (Spatial Transcriptomics Cell Segmentation) , a platform-agnostic framework that reconstructs cell-level gene expression profiles by integrating nuclei segmentation with a joint transcriptomic–spatial distance model. STCS is governed by two interpretable parameters and incorporates a reference-free parameter selection strategy based on internal stability and spatial coherence metrics, enabling adaptable deployment across tissue types and technologies without requiring matched ground-truth annotations. We benchmark STCS on a Visium HD human lung cancer dataset with matched Xenium-derived cell segmentation, enabling direct cell-level validation, and on high-resolution Stereo-seq mouse brain data to assess cross-platform generalizability. Across multiple evaluation dimensions—including cell-type agreement, spatial organization, gene-expression fidelity, and compositional accuracy—STCS achieves consistent improvements over existing methods while preserving biologically coherent spatial structure. As sequencing-based spatial transcriptomics is rapidly adopted across biomedical research, STCS provides a broadly applicable and open-source solution for reconstructing cell-resolved transcriptomes, facilitating more reliable downstream analyses and cross-platform integration.
- Open Access
- 9 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (2) , eaec0766
Impaired nitrogenous waste clearance promotes hepatocellular carcinoma
In mammals, hepatic urea cycle enzymes (UCEs) convert ammonia, the toxic nitrogenous waste, into urea for excretion. In hepatocellular carcinoma (HCC), UCE expression is often heterogeneously repressed, but its role in tumorigenesis is unclear. We show that, as in patients, UCE expression is markedly reduced in multiple HCC mouse models, including those driven by oncogenic c-MET/β-catenin, leading to impaired ammonia clearance, altered amino acid metabolism, and increased pyrimidine synthesis. In contrast, UCE expression is largely preserved in c-MET/sgAxin1 tumors, allowing assessment of the consequences of UCE loss. Silencing individual UCEs increases ammonia burden and accelerates HCC with reprogrammed amino acid and pyrimidine metabolism, supporting a causal role for defective ammonia detoxification in oncogenesis. Notably, dietary protein restriction lowers hepatic ammonia and slows tumor growth. These findings establish a mechanistic link between nitrogen overload and hepatocarcinogenesis and highlight protein restriction as a feasible therapeutic strategy for patients with impaired nitrogenous waste handling.
- 9 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (2) , eaec0766
Open AccessImpaired nitrogenous waste clearance promotes hepatocellular carcinoma
In mammals, hepatic urea cycle enzymes (UCEs) convert ammonia, the toxic nitrogenous waste, into urea for excretion. In hepatocellular carcinoma (HCC), UCE expression is often heterogeneously repressed, but its role in tumorigenesis is unclear. We show that, as in patients, UCE expression is markedly reduced in multiple HCC mouse models, including those driven by oncogenic c-MET/β-catenin, leading to impaired ammonia clearance, altered amino acid metabolism, and increased pyrimidine synthesis. In contrast, UCE expression is largely preserved in c-MET/sgAxin1 tumors, allowing assessment of the consequences of UCE loss. Silencing individual UCEs increases ammonia burden and accelerates HCC with reprogrammed amino acid and pyrimidine metabolism, supporting a causal role for defective ammonia detoxification in oncogenesis. Notably, dietary protein restriction lowers hepatic ammonia and slows tumor growth. These findings establish a mechanistic link between nitrogen overload and hepatocarcinogenesis and highlight protein restriction as a feasible therapeutic strategy for patients with impaired nitrogenous waste handling.
- Open Access
Type 2 Diabetes and Obesity Alter Exercise Training-Induced Transcriptional Adaptations to Subcutaneous White Adipose Tissue
White adipose tissue (WAT) dysfunction contributes to obesity-associated metabolic disease and type 2 diabetes (T2D). Rodent studies have demonstrated that exercise training improves WAT function, but molecular studies investigating exercise training effects on WAT in humans have been limited, particularly in the context of metabolic disease. Here, we defined the subcutaneous WAT (scWAT) transcriptome in middle-aged adults (10 male, 19 female) that were classified by lower BMI (2 ), higher BMI (≥27 kg/m 2 ), and T2D status before and after a 10-week endurance exercise regimen. At baseline, 624 genes were significantly upregulated and 112 genes downregulated in the scWAT from higher BMI participants compared to lower BMI. There was a spectrum of pathway dysregulation in scWAT in higher BMI individuals, ranging from increased markers of extracellular matrix (ECM) deposition and inflammation to decreased circadian rhythm gene expression. In people with T2D, there were additional transcriptomic differences such as translation-related pathways, selenoamino acid metabolism, and proteoglycans. Exercise training had robust effects on the transcriptome regardless of metabolic status, and notably, for the high BMI and T2D groups, training reversed several of the detrimental gene expression patterns in a cell-type-specific manner. These beneficial exercise-induced transcriptomic adaptations significantly correlated with lower levels of free fatty acids and blood pressure, particularly in participants with higher BMI and T2D. By integrating our exercise training-modulated genes with GWAS meta-analysis of physical activity, genes influenced by exercise training in the higher BMI group showed a significant enrichment in genetic associations of exercise traits in the population. A circadian rhythm-related transcription factor NR1D1 was enriched in enhancers linked with both the exercise differentially expressed genes (DEGs) and GWAS signals, suggesting a link between the circadian rhythm and training-induced adaptations. These findings demonstrate that obesity and T2D result in marked, progressive alterations in cell-type specific gene transcription in scWAT, while endurance exercise training reverses many of the metabolic disease-associated adaptations. Identification of novel molecular pathways regulated by exercise training can lead to therapeutic targets for obesity and metabolic disease.
Open AccessType 2 Diabetes and Obesity Alter Exercise Training-Induced Transcriptional Adaptations to Subcutaneous White Adipose Tissue
White adipose tissue (WAT) dysfunction contributes to obesity-associated metabolic disease and type 2 diabetes (T2D). Rodent studies have demonstrated that exercise training improves WAT function, but molecular studies investigating exercise training effects on WAT in humans have been limited, particularly in the context of metabolic disease. Here, we defined the subcutaneous WAT (scWAT) transcriptome in middle-aged adults (10 male, 19 female) that were classified by lower BMI (2 ), higher BMI (≥27 kg/m 2 ), and T2D status before and after a 10-week endurance exercise regimen. At baseline, 624 genes were significantly upregulated and 112 genes downregulated in the scWAT from higher BMI participants compared to lower BMI. There was a spectrum of pathway dysregulation in scWAT in higher BMI individuals, ranging from increased markers of extracellular matrix (ECM) deposition and inflammation to decreased circadian rhythm gene expression. In people with T2D, there were additional transcriptomic differences such as translation-related pathways, selenoamino acid metabolism, and proteoglycans. Exercise training had robust effects on the transcriptome regardless of metabolic status, and notably, for the high BMI and T2D groups, training reversed several of the detrimental gene expression patterns in a cell-type-specific manner. These beneficial exercise-induced transcriptomic adaptations significantly correlated with lower levels of free fatty acids and blood pressure, particularly in participants with higher BMI and T2D. By integrating our exercise training-modulated genes with GWAS meta-analysis of physical activity, genes influenced by exercise training in the higher BMI group showed a significant enrichment in genetic associations of exercise traits in the population. A circadian rhythm-related transcription factor NR1D1 was enriched in enhancers linked with both the exercise differentially expressed genes (DEGs) and GWAS signals, suggesting a link between the circadian rhythm and training-induced adaptations. These findings demonstrate that obesity and T2D result in marked, progressive alterations in cell-type specific gene transcription in scWAT, while endurance exercise training reverses many of the metabolic disease-associated adaptations. Identification of novel molecular pathways regulated by exercise training can lead to therapeutic targets for obesity and metabolic disease.
- Open Access
Optimized Ex Vivo Differentiation of CD103 + Dendritic Cells and High-Efficiency Retroviral Transduction of Mouse Bone Marrow HSCs
CD103 + conventional dendritic cells (cDC1s) are key drivers of antitumor immunity, but their scarcity and resistance to genetic manipulation make them difficult to study. We optimized a two-stage ex vivo culture system using key cytokines and growth factors to efficiently generate CD103 + cDC1-like cells from mouse bone marrow progenitors. These cells closely mimicked their in-vivo counterparts, displaying CD103 expression, robust cytokine production, and functional responses to immune stimulation. Additionally, we established a high-efficiency retroviral transduction method using ecotropic pseudotyped virus and retronectin-coated plates, significantly improving gene delivery into mouse hematopoietic stem cells. This integrated platform provides a powerful approach for dissecting CD103 + cDC1 biology and advancing dendritic cell–based immunotherapy research.
Open AccessOptimized Ex Vivo Differentiation of CD103 + Dendritic Cells and High-Efficiency Retroviral Transduction of Mouse Bone Marrow HSCs
CD103 + conventional dendritic cells (cDC1s) are key drivers of antitumor immunity, but their scarcity and resistance to genetic manipulation make them difficult to study. We optimized a two-stage ex vivo culture system using key cytokines and growth factors to efficiently generate CD103 + cDC1-like cells from mouse bone marrow progenitors. These cells closely mimicked their in-vivo counterparts, displaying CD103 expression, robust cytokine production, and functional responses to immune stimulation. Additionally, we established a high-efficiency retroviral transduction method using ecotropic pseudotyped virus and retronectin-coated plates, significantly improving gene delivery into mouse hematopoietic stem cells. This integrated platform provides a powerful approach for dissecting CD103 + cDC1 biology and advancing dendritic cell–based immunotherapy research.
- Open Access
- 1 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet most patients fail to achieve durable responses. To better understand the tumor microenvironment (TME), we analyze single-cell RNA-seq (~189 K cells) from 36 metastatic melanoma samples, defining 14 cell types, 55 subtypes, and 15 transcriptional hallmarks of malignant cells. Correlations between cell subtype proportions reveal six distinct clusters, with a mature dendritic cell subtype enriched in immunoregulatory molecules (mregDC) linked to naive T and B cells. Importantly, mregDC abundance predicts progression-free survival (PFS) with ICIs and other therapies, especially when combined with the TCF7 + /– CD8 T cell ratio. Analysis of an independent cohort (n = 318) validates mregDC as a predictive biomarker for anti-CTLA-4 plus anti-PD-1 therapies. Further characterization of mregDCs versus conventional dendritic cells (cDC1/cDC2) highlights their unique transcriptional, epigenetic (single-nucleus ATAC-seq data for cDCs from 14 matched samples), and interaction profiles, offering new insights for improving immunotherapy response and guiding future combination treatments.
- 1 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Open AccessMature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet most patients fail to achieve durable responses. To better understand the tumor microenvironment (TME), we analyze single-cell RNA-seq (~189 K cells) from 36 metastatic melanoma samples, defining 14 cell types, 55 subtypes, and 15 transcriptional hallmarks of malignant cells. Correlations between cell subtype proportions reveal six distinct clusters, with a mature dendritic cell subtype enriched in immunoregulatory molecules (mregDC) linked to naive T and B cells. Importantly, mregDC abundance predicts progression-free survival (PFS) with ICIs and other therapies, especially when combined with the TCF7 + /– CD8 T cell ratio. Analysis of an independent cohort (n = 318) validates mregDC as a predictive biomarker for anti-CTLA-4 plus anti-PD-1 therapies. Further characterization of mregDCs versus conventional dendritic cells (cDC1/cDC2) highlights their unique transcriptional, epigenetic (single-nucleus ATAC-seq data for cDCs from 14 matched samples), and interaction profiles, offering new insights for improving immunotherapy response and guiding future combination treatments.
- Open Access
Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma
Immune checkpoint inhibitors (ICIs) have heralded a remarkable shift in cancer care, significantly extending survival for advanced cancer patients. However, despite their remarkable clinical successes, a substantial majority of patients fail to achieve a lasting response to ICIs. To address this challenge and gain insights into the complex landscape of the tumor microenvironment (TME), we conducted an extensive analysis using single-cell RNA sequencing (scRNA; ∼216K cells across 39 samples) and single-nucleus transposase-accessible chromatin sequencing (snATAC; ∼43K cells from 15 samples) in a metastatic melanoma cohort. This systematic approach delineates 14 distinct cell types and 55 cell subtypes, including the identification of 15 transcriptional hallmarks of malignant cells. Through correlation analysis of cell subtype proportions, we unveiled six distinct clusters associated with varying tumor responses. Particularly intriguing was the identification of the mature DC enriched in immunoregulatory molecules (mregDC) subtype exhibiting correlations with naive T and B cells, forming an anti-tumor program that underscores the importance of multiple immune cell types in mediating anti-tumor immunity. Notably, we found that mregDC abundance represents a good prognostic predictor of progression-free survival (PFS) in the context of ICI treatment, and when combined with the TCF7+/- CD8 T cell ratio, it reliably predicts patient PFS across treatments beyond ICI. We validated our findings using an independent cohort of 274 ICI-treated melanoma samples analyzed using tissue-level expression. We next compared mregDCs and conventional dendritic cell types 1 and 2 (cDC1 and cDC2) using transcriptome signature, differentiation trajectory, interactome, cytokine milieu, and epigenome landscape analyses. This comparative analysis shed light on the unique attributes of mregDCs within the TME. Finally, we investigated cell type/subtype-specific genes, pathways, immune response enrichment, and ligand-receptor interactions closely associated with the proportions of mregDCs within the TME. These molecular and cellular insights, with their critical roles in enhancing the immune response against cancer, offer valuable prospects for predicting the efficacy of ICI regimens, and potentially guiding the selection of rational combinatorial therapies.
Open AccessMature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma
Immune checkpoint inhibitors (ICIs) have heralded a remarkable shift in cancer care, significantly extending survival for advanced cancer patients. However, despite their remarkable clinical successes, a substantial majority of patients fail to achieve a lasting response to ICIs. To address this challenge and gain insights into the complex landscape of the tumor microenvironment (TME), we conducted an extensive analysis using single-cell RNA sequencing (scRNA; ∼216K cells across 39 samples) and single-nucleus transposase-accessible chromatin sequencing (snATAC; ∼43K cells from 15 samples) in a metastatic melanoma cohort. This systematic approach delineates 14 distinct cell types and 55 cell subtypes, including the identification of 15 transcriptional hallmarks of malignant cells. Through correlation analysis of cell subtype proportions, we unveiled six distinct clusters associated with varying tumor responses. Particularly intriguing was the identification of the mature DC enriched in immunoregulatory molecules (mregDC) subtype exhibiting correlations with naive T and B cells, forming an anti-tumor program that underscores the importance of multiple immune cell types in mediating anti-tumor immunity. Notably, we found that mregDC abundance represents a good prognostic predictor of progression-free survival (PFS) in the context of ICI treatment, and when combined with the TCF7+/- CD8 T cell ratio, it reliably predicts patient PFS across treatments beyond ICI. We validated our findings using an independent cohort of 274 ICI-treated melanoma samples analyzed using tissue-level expression. We next compared mregDCs and conventional dendritic cell types 1 and 2 (cDC1 and cDC2) using transcriptome signature, differentiation trajectory, interactome, cytokine milieu, and epigenome landscape analyses. This comparative analysis shed light on the unique attributes of mregDCs within the TME. Finally, we investigated cell type/subtype-specific genes, pathways, immune response enrichment, and ligand-receptor interactions closely associated with the proportions of mregDCs within the TME. These molecular and cellular insights, with their critical roles in enhancing the immune response against cancer, offer valuable prospects for predicting the efficacy of ICI regimens, and potentially guiding the selection of rational combinatorial therapies.
- Open Access
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy
A central problem in cancer immunotherapy with immune checkpoint blockade (ICB) is the development of resistance, which affects 50% of patients with metastatic melanoma 1,2 . T cell exhaustion, resulting from chronic antigen exposure in the tumour microenvironment, is a major driver of ICB resistance 3 . Here, we show that CD38, an ecto-enzyme involved in nicotinamide adenine dinucleotide (NAD + ) catabolism, is highly expressed in exhausted CD8 + T cells in melanoma and is associated with ICB resistance. Tumour-derived CD38 hi CD8 + T cells are dysfunctional, characterised by impaired proliferative capacity, effector function, and dysregulated mitochondrial bioenergetics. Genetic and pharmacological blockade of CD38 in murine and patient-derived organotypic tumour models (MDOTS/PDOTS) enhanced tumour immunity and overcame ICB resistance. Mechanistically, disrupting CD38 activity in T cells restored cellular NAD + pools, improved mitochondrial function, increased proliferation, augmented effector function, and restored ICB sensitivity. Taken together, these data demonstrate a role for the CD38-NAD + axis in promoting T cell exhaustion and ICB resistance, and establish the efficacy of CD38 directed therapeutic strategies to overcome ICB resistance using clinically relevant, patient-derived 3D tumour models.
Open AccessDisrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy
A central problem in cancer immunotherapy with immune checkpoint blockade (ICB) is the development of resistance, which affects 50% of patients with metastatic melanoma 1,2 . T cell exhaustion, resulting from chronic antigen exposure in the tumour microenvironment, is a major driver of ICB resistance 3 . Here, we show that CD38, an ecto-enzyme involved in nicotinamide adenine dinucleotide (NAD + ) catabolism, is highly expressed in exhausted CD8 + T cells in melanoma and is associated with ICB resistance. Tumour-derived CD38 hi CD8 + T cells are dysfunctional, characterised by impaired proliferative capacity, effector function, and dysregulated mitochondrial bioenergetics. Genetic and pharmacological blockade of CD38 in murine and patient-derived organotypic tumour models (MDOTS/PDOTS) enhanced tumour immunity and overcame ICB resistance. Mechanistically, disrupting CD38 activity in T cells restored cellular NAD + pools, improved mitochondrial function, increased proliferation, augmented effector function, and restored ICB sensitivity. Taken together, these data demonstrate a role for the CD38-NAD + axis in promoting T cell exhaustion and ICB resistance, and establish the efficacy of CD38 directed therapeutic strategies to overcome ICB resistance using clinically relevant, patient-derived 3D tumour models.
- Open Access
Learning to Estimate Sample-specific Transcriptional Networks for 7000 Tumors
Cancers are shaped by somatic mutations, microenvironment, and patient background, each altering gene expression and regulation in complex ways, resulting in heterogeneous cellular states and dynamics. Inferring gene regulatory networks (GRNs) from expression data can help characterize this regulation-driven heterogeneity, but network inference requires many statistical samples, limiting GRNs to cluster-level analyses that ignore intra-cluster heterogeneity. We propose to move beyond coarse analyses of pre-defined subgroups by using contextualized learning, a multi-task learning paradigm that uses multi-view contexts including phenotypic, molecular, and environmental information to infer personalized models. With sample-specific contexts, contextualization enables sample-specific models and even generalizes at test time to predict network models for entirely unseen contexts. We unify three network model classes (Correlation, Markov, Neighborhood Selection) and estimate context-specific GRNs for 7997 tumors across 25 tumor types, using copy number and driver mutation profiles, tumor microenvironment, and patient demographics as model context. Our generative modeling approach allows us to predict GRNs for unseen tumor types based on a pan-cancer model of how somatic mutations affect gene regulation. Finally, contextualized networks enable GRN-based precision oncology by providing a structured view of expression dynamics at sample-specific resolution, explaining known biomarkers in terms of network-mediated effects and leading to novel subtypings that improve survival prognosis. We provide a SKLearn-style Python package https://contextualized.ml for learning and analyzing contextualized models, as well as interactive plotting tools for pan-cancer data exploration at https://github.com/cnellington/CancerContextualized . Significance Statement: Network estimation is essential for understanding the structure and function of biological systems, but current statistical approaches fail to capture inter-subject heterogeneity or cross-modality information flow, both of which are needed for understanding complex phenotypes and pathologies. We introduce contextualized network inference, leveraging multi-view contextual metadata to capture similarities and differences among heterogeneous observations during network estimation. Sharing information across contexts enables inference at sample-specific resolution, thus quantifying variation between subjects and revealing context-specific network rewiring. Applied to tumor-specific transcriptional network inference using clinical, molecular, and multi-omic data, contextualized networks improve accuracy, generalize to unseen cancer types, and discover novel prognostic tumor subtypes. By tailoring disease models to each sample, contextualized networks promise to enable precision medicine at unprecedented resolution.
Open AccessLearning to Estimate Sample-specific Transcriptional Networks for 7000 Tumors
Cancers are shaped by somatic mutations, microenvironment, and patient background, each altering gene expression and regulation in complex ways, resulting in heterogeneous cellular states and dynamics. Inferring gene regulatory networks (GRNs) from expression data can help characterize this regulation-driven heterogeneity, but network inference requires many statistical samples, limiting GRNs to cluster-level analyses that ignore intra-cluster heterogeneity. We propose to move beyond coarse analyses of pre-defined subgroups by using contextualized learning, a multi-task learning paradigm that uses multi-view contexts including phenotypic, molecular, and environmental information to infer personalized models. With sample-specific contexts, contextualization enables sample-specific models and even generalizes at test time to predict network models for entirely unseen contexts. We unify three network model classes (Correlation, Markov, Neighborhood Selection) and estimate context-specific GRNs for 7997 tumors across 25 tumor types, using copy number and driver mutation profiles, tumor microenvironment, and patient demographics as model context. Our generative modeling approach allows us to predict GRNs for unseen tumor types based on a pan-cancer model of how somatic mutations affect gene regulation. Finally, contextualized networks enable GRN-based precision oncology by providing a structured view of expression dynamics at sample-specific resolution, explaining known biomarkers in terms of network-mediated effects and leading to novel subtypings that improve survival prognosis. We provide a SKLearn-style Python package https://contextualized.ml for learning and analyzing contextualized models, as well as interactive plotting tools for pan-cancer data exploration at https://github.com/cnellington/CancerContextualized . Significance Statement: Network estimation is essential for understanding the structure and function of biological systems, but current statistical approaches fail to capture inter-subject heterogeneity or cross-modality information flow, both of which are needed for understanding complex phenotypes and pathologies. We introduce contextualized network inference, leveraging multi-view contextual metadata to capture similarities and differences among heterogeneous observations during network estimation. Sharing information across contexts enables inference at sample-specific resolution, thus quantifying variation between subjects and revealing context-specific network rewiring. Applied to tumor-specific transcriptional network inference using clinical, molecular, and multi-omic data, contextualized networks improve accuracy, generalize to unseen cancer types, and discover novel prognostic tumor subtypes. By tailoring disease models to each sample, contextualized networks promise to enable precision medicine at unprecedented resolution.